Deal Dispatch: Nvidia Buys Hugging Face for $12.9 Billion, Barilla Acquires Goodles, Park Place Partners Bankruptcy
Major M&A deals include Flex buys EPC Power for $4.4 Billion, KKR acquires A1 Garage Door, Starman Optical Buys GoPro.
Stocks · News reference
Sangamo Therapeutics Files For Chapter 11 Bankruptcy, Secures Up To $30M In Debtor-In-Possession Financing; Launches Court-Supervised Asset Sale Process With Eli Lilly And Astellas As Stalking Horse Bidders For Key Gene Therapy, Genome Editing, And Fabry Disease Assets; Expects Restructuring To Result In Elimination Of About 51 Roles In U.S., Or About 40% Of Company's Workforce
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
Nxera Pharma announced it will receive an $8.6 million milestone payment from Centessa Pharmaceuticals (a subsidiary of Eli Lilly) following late-stage development progress on selective orexin receptor 2 (OX2R) agonist candidates. The payment will be recognized as revenue in Q3 2026. Nxera retains rights to future development, commercialization milestones, and royalties from the OX2R agonist programs.
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
Hims & Hers reported Q2 2026 revenue of $753.2M, up 38.2% YoY, driven by subscriber growth to 2.9M and higher spending per subscriber. The company raised full-year 2026 revenue guidance to $3.1B-$3.3B (32-41% growth). However, gross margins contracted sharply to 63.8% due to lower-margin weight loss products and international expansion, resulting in an $86.3M net loss and widening loss per share estimates.
Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ
Fidelity's FHLC and Invesco's IBBQ offer different healthcare investment strategies. FHLC provides broad exposure to 365 healthcare holdings with a lower 0.08% expense ratio and 1.2% dividend yield, while IBBQ focuses on biotech with higher volatility, delivering 56.4% 1-year returns but experiencing a 37.9% maximum drawdown. The choice depends on investor risk tolerance and diversification preferences.